Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14591142 | 0.75 | MAOA (0.32) | MAOAMAOBTSHRCA1CA2 | |
| SCHEMBL8535446 | 0.75 | MAOA (0.39) | MAOAMAOBTSHRCA1CA2 | |
| SCHEMBL25345416 | 0.69 | TRPA1 (0.33) | — | |
| SCHEMBL29471383 | 0.67 | — | — | |
| SCHEMBL59871 | 0.67 | — | — | |
| SCHEMBL30473446 | 0.67 | TSHR (0.42) | MAOAMAOBTSHRCA1CA2 | |
| SCHEMBL4486486 | 0.67 | TSHR (0.42) | MAOAMAOBTSHRCA1CA2 | |
| SCHEMBL19348293 | 0.67 | OXTR (0.41) | MAOAMAOBTSHRNPC1RAB9A | |
| Ammonia Solution, Strong SCHEMBL23320033 | 0.65 | MAOA (0.40) | MAOAMAOBTSHRCA1CA2 | |
| SCHEMBL16439994 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023148206-A1 | MICROBIOCIDAL N-AMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-08-10 | — | — | WO | claimed |
| EP-2134342-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-30 | — | — | EP | claimed |
| CN-117642185-A | Improved CD30 targeting antibody drug conjugates and uses thereof | 路德维希-马克西米利安慕尼黑大学 | 2024-03-01 | — | — | CN | disclosed |
| WO-2024010015-A1 | PYRIMIDINE DERIVATIVES | あすか製薬株式会社 | 2024-01-11 | — | — | WO | disclosed |
| WO-2023148206-A1 | MICROBIOCIDAL N-AMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| US-11542261-B2 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220213094-A1 | Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-07-07 | — | — | US | disclosed |
| CN-108137513-B | Pyrimidine derivatives | ASKA 制药株式会社 | 2022-03-01 | — | — | CN | disclosed |
| US-11254667-B2 | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-02-22 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3372589-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2021-10-20 | — | — | EP | disclosed |
| EP-0627400-A1 | Aromatic acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0612729-A2 | Pyridine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1994-08-31 | — | — | EP | disclosed |
| EP-0611769-A1 | Silylated acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0291787-B1 | Novel substituted silyl alkylene amines | MERRELL DOW PHARMA (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5246948-A | Antiinflammatory, antipyretic, analgesic, antiallergic, immunosupressing or immunomodulating activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-21 | — | — | US | disclosed |
| EP-0522606-A2 | Pyridine derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-01-13 | — | — | EP | disclosed |
| EP-0409676-A1 | Novel acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-01-23 | — | — | EP | disclosed |
| EP-0403713-A1 | Novel acetylcholinesterase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-12-27 | — | — | EP | disclosed |
| EP-0291787-A1 | Novel substituted silyl alkylene amines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254667-B2 | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors | IRAK1, IRAK4, FLT3 | MAOA 2475/4885MAOB 2677/4885TSHR 2789/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | MAOA 123/4885MAOB 178/4885TSHR 1591/4885 |
| US-20220213094-A1 | Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | IRAK1, IRAK4, FLT3 | MAOA 2515/4885MAOB 2629/4885TSHR 2908/4885 |
| US-11542261-B2 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors | IRAK1, IRAK4, IRAK2 | MAOA 3606/4885MAOB 3580/4885TSHR 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.